HomeCompareMSTW vs ABBV

MSTW vs ABBV: Dividend Comparison 2026

MSTW yields 195.88% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MSTW wins by $105.75M in total portfolio value
10 years
MSTW
MSTW
● Live price
195.88%
Share price
$6.17
Annual div
$12.09
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$105.86M
Annual income
$52,815,411.45
Full MSTW calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — MSTW vs ABBV

📍 MSTW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMSTWABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MSTW + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MSTW pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MSTW
Annual income on $10K today (after 15% tax)
$16,649.45/yr
After 10yr DRIP, annual income (after tax)
$44,893,099.73/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, MSTW beats the other by $44,872,043.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MSTW + ABBV for your $10,000?

MSTW: 50%ABBV: 50%
100% ABBV50/50100% MSTW
Portfolio after 10yr
$52.98M
Annual income
$26,420,091.61/yr
Blended yield
49.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

MSTW
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MSTW buys
0
ABBV buys
0
No recent congressional trades found for MSTW or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMSTWABBV
Forward yield195.88%3.06%
Annual dividend / share$12.09$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$105.86M$102.3K
Annual income after 10y$52,815,411.45$24,771.77
Total dividends collected$99.64M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MSTW vs ABBV ($10,000, DRIP)

YearMSTW PortfolioMSTW Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$30,288$19,587.59$11,550$430.00+$18.7KMSTW
2$87,853$55,444.92$13,472$627.96+$74.4KMSTW
3$244,305$150,303.17$15,906$926.08+$228.4KMSTW
4$652,034$390,627.48$19,071$1,382.55+$633.0KMSTW
5$1,672,030$974,352.86$23,302$2,095.81+$1.65MMSTW
6$4,124,174$2,335,102.64$29,150$3,237.93+$4.10MMSTW
7$9,795,753$5,382,886.78$37,536$5,121.41+$9.76MMSTW
8$22,430,476$11,949,020.11$50,079$8,338.38+$22.38MMSTW
9$49,571,695$25,571,085.69$69,753$14,065.80+$49.50MMSTW
10$105,857,125$52,815,411.45$102,337$24,771.77+$105.75MMSTW

MSTW vs ABBV: Complete Analysis 2026

MSTWStock

The Roundhill MSTR WeeklyPay ETF (“MSTW”) is designed for investors seeking a combination of income and growth potential. MSTW aims to provide weekly distributions and calendar week returns, before fees and expenses, equal to 1.2 times (120%) the calendar week total return of MicroStrategy common shares (Nasdaq: MSTR). MSTW is an actively-managed ETF.

Full MSTW Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this MSTW vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MSTW vs SCHDMSTW vs JEPIMSTW vs OMSTW vs KOMSTW vs MAINMSTW vs JNJMSTW vs MRKMSTW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.